Ameloblastoma

Summary

Ameloblastoma (MONDO:0017795) is a disease and 7 clinical trials. Top therapeutic interventions include dabrafenib, tetracycline, and trametinib. A subtype of musculoskeletal system benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ameloblastoma
Mondo ID	MONDO:0017795
MeSH	D000564
Orphanet	314419
DOID	DOID:0050894
NCIT	C4313
SNOMED CT	285311001
UMLS	C0002448
MedGen	1457
GARD	0005747
MedDRA	10066796
NORD	764
Is cancer (heuristic)	no

Also known as: adamantinoma · Adenoameloblastoma · adenomatoid odontogenic tumor · adenomatoid odontogenic tumour · ameloblastoma · ameloblastoma of jaw · aot

Data availability: 5 cell lines.

Disease family

This is a subtype of musculoskeletal system benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › ameloblastoma

Related subtypes (7): benign connective and soft tissue neoplasm, chondroma, benign muscle neoplasm, benign uterine ligament neoplasm, benign neoplasm of sternum, benign neoplasm of gum, benign skeletal muscle neoplasm

Subtypes (4): bone ameloblastoma, desmoplastic ameloblastoma, plexiform ameloblastoma, adenoid ameloblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Dabrafenib	Approved (phase 3)

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Trametinib	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06819605	PHASE2/PHASE3	NOT_YET_RECRUITING	Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
NCT06264778	PHASE3	UNKNOWN	Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma
NCT06653517	PHASE2	RECRUITING	Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
NCT02367859	PHASE2	COMPLETED	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
NCT07306962	Not specified	RECRUITING	Virtual Lesion Segmentation and Mandibular Ameloblastoma Radiographic Safety Margin
NCT04157374	Not specified	WITHDRAWN	Action Observation Training in Patients With Chronic Low Back Pain
NCT06759610	Not specified	COMPLETED	Effect of Tetracycline Socked Pack on Acceleration of Healing During Marsupialization

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DABRAFENIB	4	4
TETRACYCLINE	4	1
TRAMETINIB	4	1
CHEMBL5433950	0	1
CHEMBL5093910	0	1